ERBB2 and breast carcinoma: Breast at present, the research hotspots of breast cancer still lie in the differentiation of benign and malignant BC (2) and the evaluation of treatment efficacy, etc. Neoadjuvant chemotherapy (NAC) has emerged as a crucial treatment modality for locally advanced breast cancer (LABC), especially in triple negative and human epidermal growth factor receptor 2 (HER2) positive BC, by reducing tumor burden, decreasing tumor stage, and increasing the possibility of breast-conserving surgery (3, 4).